Identification and initial structure-activity relationships of a novel non-peptide quinolone GnRH receptor antagonist
作者:Robert J. DeVita、Darius D. Hollings、Mark T. Goulet、Matthew J. Wyvratt、Michael H. Fisher、Jane-L. Lo、Yi Tien Yang、Kang Cheng、Roy G. Smith
DOI:10.1016/s0960-894x(99)00446-1
日期:1999.9
Screening of the Merck sample collection for non-peptide compounds with binding affinity for the rat GnRH receptor led to the identification of the substituted quinolone (1) as a lead compound in the search for a non-peptide GnRH receptor antagonist. Substantial improvements in potency (similar to 300 fold) were achieved by addition of an alkyl amine at the 4-position, a 3,5-dimethylphenyl group at the 3-position and 6-nitro-7-chloro-substitution of the 1H-quinolone core. (C) 1999 Elsevier Science Ltd. All rights reserved.
3-(Methyleneaminoxy)methylpiperidine derivatives as uptake inhibitors of biogenic amines in the brain synaptosomal fraction
A series of 3-(methyleneaminoxy)methylpiperidines (5a-h) and their corresponding N-methyl derivatives (6a-h) with a variety of substituents on the imino carbon were synthesized and tested for their potential antidepressant properties; their capacity to inhibit the re-uptake of biogenic amines (NA, 5-HT and DA) in rabbit brain synaptosomal fractions was also evaluated. The biological results obtained for the piperidine derivatives 5a-h and 6a-h and viloxazine 1, the reference drug, on the 3 re-uptake systems revealed that compounds 5 and 6 are generally able to inhibit biogenic amine uptake. The IC50 values for 5 and 6 were often lower than that of viloxazine 1, in particular for the serotonin- and/or dopamine-uptake systems. A higher activity was found for compounds substituted with at least one phenyl ring on the imino carbon with respect to completely aliphatic systems, and for N-unsubstituted compounds with respect to N-methyl-substituted compounds.
Methods and compositions for treating amyloid-related diseases
申请人:Kong Xianqi
公开号:US20060223855A1
公开(公告)日:2006-10-05
Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.